Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Exec VP-Commercial Operations Joins From Amgen

This article was originally published in The Pink Sheet Daily

Executive Summary

Kevin Young will oversee global commercial operations and strategy for Gilead’s product portfolio, including the launch of the HIV combination therapy Truvada. At Amgen, he headed the U.S. Inflammation Business Unit and oversaw the relaunch of Enbrel.

You may also be interested in...



GSK, Gilead HIV Fixed-Dose Combination Drugs Clear FDA

The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel